Atle Fund Management AB Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001381843

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q3 2026 · 39 positions · Total reported value $373.39M · Top-10 concentration 53.9% · Updated 2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

Turnover: 53.5% · 4 new · 15 cut · 4 exited

Active Share (vs S&P 500): 94.8% · vs QQQ: 98.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -10.0% · vs SPY -12.1% · Prev Value $371.70M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +5.6% · vs SPY +3.4% · Latest Value $373.39M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Atle Fund Management AB disclosed 39 equity positions with a combined reported value of $373.39M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 53.9% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were LLY ($36.10M), MRK ($24.56M), JNJ ($24.19M). By sector, the heaviest allocations are Health Care 90.6%, Industrials 6.2%. Versus the prior quarter, allocation shifted toward Industrials (+2.5pp) and away from Consumer Staples (-0.9pp), Health Care (-1.6pp).

Versus the prior quarter, Atle Fund Management AB opened 4 new positions, trimmed 15 and fully exited 4, a turnover rate of 53.5% of positions. The portfolio's overlap with the prior quarter was 81% of names.

The largest new positions opened in Q3 2026 were SMMT ($3.12M), CMPS ($3.03M), PVLA ($2.06M).

Of the 4 positions fully exited versus the prior quarter, the largest were IONS ($10.87M), BCAX ($4.32M), CMPX ($2.30M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • SMMT SUMMIT THERAPEUTICS INC · $3.12M
  • CMPS COMPASS PATHWAYS PLC · $3.03M
  • PVLA PALVELLA THERAPEUTICS INC NE · $2.06M
  • MANE VERADERMICS INC · $1.23M

Fully Exited (vs previous quarter)

  • IONS IONIS PHARMACEUTICALS INC · prev qtr: $10.87M
  • BCAX BICARA THERAPEUTICS INC · prev qtr: $4.32M
  • CMPX COMPASS THERAPEUTICS INC · prev qtr: $2.30M
  • JBIO JADE BIOSCIENCES INC · prev qtr: $1.97M

Insider Transactions (Form 4)

Latest Atle Fund Management AB buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Atle Fund Management AB files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 39 positions worth $371.70M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Portfolio Structure

  • 39 positions · $371.70M reported value (Q2 2026)
  • Top 10 holdings = 48.0% of reported value
  • Largest position: LLY (ELI LILLY & CO) at 9.6%
  • Average position size: $9.53M

Sector Tilt

  • Health Care 92.2%
  • Consumer Staples 4.1%
  • Industrials 3.8%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 16 added, 20 reduced, 3 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively increasing exposure to healthcare (70% of top-10 holdings), particularly biotech/pharma, while modestly reducing some positions, suggesting a bullish stance on healthcare innovation and selective profit-taking. 2. Key moves: - Added: JNJ (+0.64% wt), ABBV (+2.04% wt), TMO (+2.46% wt), BIIB (+0.64% wt), VRTX (+1.38% wt), ONC (+0.80% wt). - Reduced: MRK (-0.03% wt), RVMD (-0.05% wt), CVS (-0.87% wt). 3. Portfolio structure: Active, concentrated (39 positions), with heavy healthcare bias (90% of top-10) and high risk appetite (biotech/tech focus). 4. Per-holding one-liner: - LLY (Eli Lilly: diabetes/obesity drugs), MRK (Merck: oncology/immunology), JNJ (Johnson & Johnson: healthcare/pharma), ABBV (AbbVie: immunology/oncology), TMO (Thermo Fisher: lab equipment), BIIB (Biogen: neurology), VRTX (Vertex: cystic fibrosis), RVMD (Revolution Medicines: cancer), ONC (Beone Medicines: oncology), CVS (CVS Health: retail pharmacy). 5. Style summary: Aggressive healthcare tilt with biotech conviction, selectively trimming winners to fund new bets.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-13 03:24

Sector Allocation

Health Care 90.6%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 31.20K $36.10M 9.67%
9.67%
Add
2 168.99K $24.56M 6.58%
6.58%
Reduce
3 91.39K $24.19M 6.48%
6.48%
Add
4 91.29K $23.88M 6.40%
6.40%
Add
5 34.41K $23.23M 6.22%
6.22%
Add
6 70.95K $16.03M 4.29%
4.29%
Add
7 28.16K $14.72M 3.94%
3.94%
Add
8 66.11K $13.57M 3.63%
3.63%
Reduce
9 35.68K $13.06M 3.50%
3.50%
Add
10 139.31K $11.94M 3.20%
3.20%
Reduce
11 36.11K $10.84M 2.90%
2.90%
Add
12 163.70K $10.77M 2.88%
2.88%
Add
13 25.65K $10.43M 2.79%
2.79%
Add
14 87.47K $9.98M 2.67%
2.67%
Add
15 109.65K $9.46M 2.54%
2.54%
Add
16 34.30K $9.44M 2.53%
2.53%
Add
17 77.38K $9.39M 2.52%
2.52%
Add
18 28.07K $9.34M 2.50%
2.50%
Add
19 89.25K $7.70M 2.06%
2.06%
Add
20 303.82K $7.39M 1.98%
1.98%
Add
21 54.10K $6.15M 1.65%
1.65%
Hold
22 40.46K $6.03M 1.61%
1.61%
Reduce
23 70.07K $5.99M 1.60%
1.60%
Reduce
24 26.73K $5.95M 1.59%
1.59%
Add
25 130.62K $5.70M 1.53%
1.53%
Reduce
26 136.22K $5.52M 1.48%
1.48%
Reduce
27 38.61K $5.48M 1.47%
1.47%
Reduce
28 184.39K $4.60M 1.23%
1.23%
Reduce
29 46.45K $4.60M 1.23%
1.23%
Reduce
30 44.24K $3.94M 1.05%
1.05%
Reduce
31 43.18K $3.60M 0.96%
0.96%
Reduce
32 93.55K $3.59M 0.96%
0.96%
Reduce
33 184.69K $3.12M 0.84%
0.84%
New
34 243.51K $3.03M 0.81%
0.81%
New
35 43.68K $2.86M 0.77%
0.77%
Hold
36 29.89K $2.38M 0.64%
0.64%
Reduce
37 14.92K $2.06M 0.55%
0.55%
New
38 663.77K $1.55M 0.41%
0.41%
Reduce
39 10.11K $1.23M 0.33%
0.33%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 80% R 80% F1 80% (modelled on 2026-Q2; 8/10 hit)

Low-confidence forecast This fund replaces about 26% of its Top-10 each quarter and backtests at F1 77% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 77% · recall 77% · F1 77% · avg rank error 2.2 · Top-10 turnover 26%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q2 70% 70% 70% MRK · LLY · UNH · TMO · NBIX · HRMY · ABBV · SYK · AMGN · REGN LLY · UNH · MRK · TMO · AMGN · BSX · REGN · VRTX · COR · SYK
2024-Q3 90% 90% 90% LLY · UNH · MRK · TMO · AMGN · BSX · REGN · VRTX · SYK · COR LLY · UNH · MRK · TMO · AMGN · BSX · ABBV · SYK · COR · VRTX
2024-Q4 80% 80% 80% LLY · UNH · MRK · TMO · AMGN · ABBV · BSX · SYK · COR · VRTX LLY · UNH · ABBV · BSX · TMO · MRK · SYK · NBIX · ALKS · VRTX
2025-Q1 80% 80% 80% LLY · ABBV · UNH · BSX · TMO · NBIX · MRK · SYK · ALKS · VRTX LLY · ABBV · UNH · BSX · MRK · TMO · VRTX · COR · GILD · SYK
2025-Q2 80% 80% 80% LLY · ABBV · BSX · UNH · VRTX · TMO · MRK · GILD · COR · NBIX LLY · ABBV · BSX · NBIX · MRK · SYK · VRTX · ISRG · TMO · COR
2025-Q3 70% 70% 70% LLY · ABBV · BSX · NBIX · MRK · SYK · VRTX · ISRG · TMO · COR LLY · ABBV · NBIX · MRK · TMO · ONC · BBIO · COR · ISRG · GILD
2025-Q4 80% 80% 80% LLY · ABBV · NBIX · MRK · TMO · ONC · BBIO · ISRG · COR · GILD LLY · ABBV · MRK · TMO · NBIX · ISRG · ONC · BBIO · VRTX · BSX
2026-Q1 80% 80% 80% LLY · ABBV · MRK · TMO · NBIX · ISRG · ONC · BBIO · VRTX · BSX LLY · MRK · TMO · ONC · JNJ · BBIO · VRTX · ABBV · SYK · ISRG
2026-Q2 60% 60% 60% LLY · MRK · TMO · ONC · JNJ · VRTX · BBIO · ISRG · MIRM · ABBV LLY · MRK · JNJ · ABBV · CVS · TMO · RVMD · BIIB · NBIX · MIRM
2026-Q3 ★ 80% 80% 80% LLY · MRK · JNJ · CVS · ABBV · RVMD · TMO · BIIB · MIRM · IONS LLY · MRK · JNJ · ABBV · TMO · BIIB · VRTX · RVMD · ONC · CVS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-11. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-11 Trading days30 Holdings17 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-11, and will update as prices arrive.

Portfolio return+8.32%Buy & hold
QQQ synthetic benchmark-11.15%Liquidity weighted
Excess return+19.47%vs benchmark
Barra annualised vol18.2%Model estimate
Realised vol21.0%Annualised in window
Weighted beta0.42Raw exposure
Factor / specific risk74% / 26%Share of variance
Top-10 concentration79.1%Of reported value
Portfolio value (start = 100)78.086.194.3102.4110.610-0110-2211-11Atle Fund Management ABQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+8.32%Disclosed long book
QQQ synthetic benchmark-11.15%Liquidity-weighted constituents
Model universe, equal weight+2.07%Opportunity-cost reference
Excess return+19.47%Portfolio − benchmark
Arithmetic return sum+8.25%Difference vs compounded is the cross term
Weighted raw beta0.42Weighted holding betas
Realised volatility (annualised)20.99%Daily returns in window
Barra model volatility (annualised)18.15%Factor + specific
Factor share of variance74.5%Barra factors
Specific share of variance25.5%Stock residuals
Reported value$247.9M13F long US equity

2. Return attribution

The +8.25% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +0.14% 1.6%
Momentum & Growth 3 -2.07% -25.1%
Volatility & Tail Risk 7 +2.88% 35.0%
Industry 12 +9.15% 110.9%
Specific 1 -1.84% -22.4%
Return attribution (style + industry, %)-8.8-4.4+0.0+4.4+8.8Size-0.28Max Drawdown-0.31Industrials+0.33Consumer Staples+0.70Leverage (Downside Vol)+0.93Mid Cap-1.01Residual Volatility+1.39Turnover+1.48Momentum-1.90Beta-2.25Skewness-2.50Kurtosis+2.61Historical Volatility+3.01Health Care+8.12
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +0.86 +9.47% +8.12% 98.4%
Historical Volatility Style -0.31 -9.82% +3.01% 36.4%
Kurtosis Style +0.42 +6.17% +2.61% 31.7%
Turnover Style -0.34 -4.35% +1.48% 17.9%
Residual Volatility Style +0.65 +2.15% +1.39% 16.8%
Leverage (Downside Vol) Style -0.31 -3.05% +0.93% 11.3%
Consumer Staples Industry +0.05 +14.46% +0.70% 8.4%
Industrials Industry +0.09 +3.55% +0.33% 4.0%
Growth Style -0.11 +1.50% -0.16% -2.0%
Size Style +0.15 -1.93% -0.28% -3.4%
Max Drawdown Style +0.31 -1.01% -0.31% -3.8%
Mid Cap Style +0.53 -1.92% -1.01% -12.2%
Specific Specific — — -1.84% -22.4%
Momentum Style +0.57 -3.32% -1.90% -23.1%
Beta Style -0.46 +4.92% -2.25% -27.2%
Skewness Style +0.52 -4.77% -2.50% -30.2%

3. Risk attribution

Annualised volatility is 18.15%; factor risk explains 74.5% of variance and specific risk 25.5%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-61.5-30.8+0.0+30.8+61.5Beta-2.63Max Drawdown-1.78Size-0.81Residual Volatility-0.35Skewness+0.50Consumer Staples+1.44Leverage (Downside Vol)+1.54Mid Cap+1.71Industrials+2.16Kurtosis+2.89Historical Volatility+3.72Momentum+7.89Specific+25.50Health Care+56.97
Factor Type Exposure Share of variance Vol contribution Share of vol
Health Care Industry +0.86 57.0% +10.34% 10.3%
Specific Specific — 25.5% +4.63% 4.6%
Momentum Style +0.57 7.9% +1.43% 1.4%
Historical Volatility Style -0.31 3.7% +0.68% 0.7%
Kurtosis Style +0.42 2.9% +0.52% 0.5%
Industrials Industry +0.09 2.2% +0.39% 0.4%
Mid Cap Style +0.53 1.7% +0.31% 0.3%
Leverage (Downside Vol) Style -0.31 1.5% +0.28% 0.3%
Consumer Staples Industry +0.05 1.4% +0.26% 0.3%
Skewness Style +0.52 0.5% +0.09% 0.1%
Non-linear Size Style -0.12 0.3% +0.06% 0.1%
Growth Style -0.11 0.3% +0.05% 0.1%
Amihud Illiquidity Style -0.08 0.2% +0.04% 0.0%
Liquidity Style +0.10 0.2% +0.04% 0.0%
Residual Volatility Style +0.65 -0.3% -0.06% -0.1%
Size Style +0.15 -0.8% -0.15% -0.1%
Max Drawdown Style +0.31 -1.8% -0.32% -0.3%
Beta Style -0.46 -2.6% -0.48% -0.5%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-0.9-0.10.71.62.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size +0.14 +2.10 -1.95
Non-linear Size -0.12 +1.68 -1.80
Mid Cap +0.53 +0.13 +0.40
Beta -0.46 +1.29 -1.75
Momentum +0.57 +0.72 -0.14
Short-term Reversal -0.01 -0.64 +0.64
Residual Volatility +0.65 -0.40 +1.05
Historical Volatility -0.31 +0.86 -1.17
Liquidity +0.10 +0.11 -0.01
Amihud Illiquidity -0.08 +1.16 -1.24
Turnover -0.34 +0.21 -0.55
Growth -0.11 +0.58 -0.69
Leverage (Downside Vol) -0.31 +0.14 -0.45
Skewness +0.52 +0.24 +0.29
Kurtosis +0.42 +0.21 +0.21
Max Drawdown +0.31 -0.08 +0.39

5. Industry allocation & Brinson

Industry allocation (weight, %)-8.617.242.968.694.4Information TechnologyCommunication ServicesUtilitiesConsumer DiscretionaryConsumer StaplesIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -16.67% +4.61% +12.27% -12.27% +12.27%
Health Care 85.8% 1.7% +8.46% +9.50% +16.73% -0.02% -0.87% +7.10%
Communication Services 0.0% 2.6% +0.00% -12.15% +0.05% +0.32% -0.32% +0.32%
Consumer Staples 4.8% 0.8% +4.47% +15.33% +1.02% -0.09% -0.43% +0.09%
Utilities 0.0% 0.8% +0.00% +10.14% -0.16% -0.08% +0.08% -0.08%
Industrials 9.4% 11.1% +6.32% +7.87% -0.32% -0.17% +0.03% -0.28%
Consumer Discretionary 0.0% 8.8% +0.00% +5.93% -1.44% -0.52% +0.52% -0.52%
Total +20.41% +11.67% -13.23% +18.86%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
LLY ELI LILLY & CO Health Care 14.57% +24.22% +3.53% Add
MRK MERCK & CO INC Health Care 9.91% +1.29% +0.13% Reduce
JNJ JOHNSON & JOHNSON Health Care 9.76% +5.92% +0.58% Add
ABBV ABBVIE INC Health Care 9.63% +12.76% +1.23% Add
TMO THERMO FISHER SCIENTIFIC INC Industrials 9.37% +6.32% +0.59% Add
VRTX VERTEX PHARMACEUTICALS INC Health Care 5.94% +4.63% +0.27% Add
RVMD REVOLUTION MEDICINES INC Health Care 5.47% -11.96% -0.66% Reduce
ONC BEONE MEDICINES LTD Health Care 5.27% +14.77% +0.78% Add
CVS CVS HEALTH CORP Consumer Staples 4.82% +4.47% +0.21% Reduce
BBIO BRIDGEBIO PHARMA INC Health Care 4.35% +20.88% +0.91% Add
ISRG INTUITIVE SURGICAL INC Health Care 4.21% +10.55% +0.44% Add
INSM INSMED INC Health Care 4.03% +5.79% +0.23% Add
DXCM DEXCOM Health Care 3.11% -6.89% -0.21% Add
NAMS NEWAMSTERDAM PHARMA CO NV Health Care 2.98% -14.80% -0.44% Add
GILD GILEAD SCIENCES INC Health Care 2.43% +13.88% +0.34% Reduce
BSX BOSTON SCIENTIFIC CORP Health Care 2.30% +3.39% +0.08% Reduce
TNGX Tango Therapeutics, Inc. Health Care 1.86% +3.13% +0.06% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 LLY Health Care 14.57% +24.22% +3.53%
2 ABBV Health Care 9.63% +12.76% +1.23%
3 BBIO Health Care 4.35% +20.88% +0.91%
4 ONC Health Care 5.27% +14.77% +0.78%
5 TMO Industrials 9.37% +6.32% +0.59%
6 JNJ Health Care 9.76% +5.92% +0.58%
7 ISRG Health Care 4.21% +10.55% +0.44%
8 GILD Health Care 2.43% +13.88% +0.34%
9 BSX Health Care 2.30% +3.39% +0.08%
10 TNGX Health Care 1.86% +3.13% +0.06%
11 DXCM Health Care 3.11% -6.89% -0.21%
12 NAMS Health Care 2.98% -14.80% -0.44%
13 RVMD Health Care 5.47% -11.96% -0.66%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-11 (30 trading days), the reported portfolio returned +8.32%, versus -11.15% for the QQQ synthetic benchmark — an excess of +19.47%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +8.12%, Historical Volatility +3.01%, Kurtosis +2.61%; the largest drags came from Skewness -2.50%, Beta -2.25%, Momentum -1.90%. Specific (stock-level) return contributed -1.84%.
  3. Risk attribution: Barra model volatility is 18.15% annualised; factor risk explains 74% of variance and specific risk 26%. The largest factor risk sources are Health Care 57.0%, Momentum 7.9%, Historical Volatility 3.7%.
  4. Style tilt: size +0.14, momentum +0.57, volatility -0.31, liquidity +0.10; the weighted raw beta is 0.42. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+84.1 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +20.41%, selection +11.67% and interaction -13.23%.
  6. Concentration: the top-10 positions are 79.1% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Atle Fund Management AB buy in 2026-Q3?

In its 2026-Q3 13F filing, Atle Fund Management AB reported 39 equity positions worth $373.39M in aggregate; its largest disclosed positions were LLY ($36.10M), MRK ($24.56M), JNJ ($24.19M).

How large is Atle Fund Management AB's portfolio?

Atle Fund Management AB reported $373.39M of long equity holdings across 39 positions as of 2026-Q3. Top-10 holdings account for 53.9% of reported value.

What is Atle Fund Management AB's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/atle-fund-management-ab/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →